Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04141709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer

Study acronym: OLI-CR-P
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Feb 28, 2024 to Apr 28, 2027v6 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 4
    • Study completion date: Feb 28, 2025 to Apr 28, 2027
    • Study description revised
  2. Primary completion date: Dec 31, 2022 to Feb 28, 2024
    • Study completion date: Dec 31, 2023 to Feb 28, 2025
    • Eligibility criteria expanded, about 6 words
    v5
  3. Phase: Phase 2 to Not applicablev4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  5. Secondary endpoints: 9 to 6v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer. The effectiveness will be tested in comparison to an observation group, in which no further therapy is initially given. Treatment can be stereotactically hypofractionated or conventionally fractionated.
Trial Details
NCT Number NCT04141709
Lead Sponsor Technische Universität Dresden
Conditions
(from sponsor)		 Oligometastatic Disease, Prostatic Cancer, Castration-Resistant
Related terms Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov